| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 161 | 21 |
| Net increase in cash, cash equivalents and restricted cash | 133,541 | 130,284 |
| Cash and cash equivalents at beginning of period | 561,380 | - |
| Cash and cash equivalents at end of period | 694,921 | - |
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)